Vaxart Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

false 0000072444 0000072444 2025-09-02 2025-09-02

 

 

 

Date of Report (Date of earliest event reported): September 2, 2025

 

 

 

 

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

On September 2, 2025, Michael J. Finney, Ph.D. provided notice of his retirement from the board of directors (the “Board”) of Vaxart, Inc. (the “Company”), including as Chair of the Board and as Chair and a member of the Science and Technology Committee, effective September 30, 2025. Dr. Finney’s retirement was for personal reasons and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

In connection with Dr. Finney’s retirement from the Board, the Board reduced the size of the Board from six to five members, effective upon the retirement of Dr. Finney.

 

 

On September 2, 2025, the Company issued a press release regarding Dr. Finney’s retirement from the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof regardless of any general incorporation language in such filing.

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.